Kyverna Therapeutics (NASDAQ:KYTX) Upgraded by Wall Street Zen to “Hold” Rating

Wall Street Zen upgraded shares of Kyverna Therapeutics (NASDAQ:KYTX) from a sell rating to a hold rating in a research report report published on Sunday.

Several other equities analysts have also recently weighed in on KYTX. Wells Fargo & Company raised their price target on Kyverna Therapeutics from $31.00 to $33.00 and gave the company an “overweight” rating in a report on Tuesday, December 16th. HC Wainwright upped their price objective on Kyverna Therapeutics from $10.00 to $20.00 and gave the stock a “buy” rating in a report on Monday, October 27th. Morgan Stanley set a $33.00 target price on Kyverna Therapeutics in a research report on Monday, December 15th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Kyverna Therapeutics in a research report on Monday, December 29th. Four analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Kyverna Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $28.67.

Kyverna Therapeutics Stock Performance

Shares of NASDAQ KYTX opened at $8.32 on Friday. The company has a market cap of $364.42 million, a P/E ratio of -2.23 and a beta of 3.45. Kyverna Therapeutics has a 52-week low of $1.78 and a 52-week high of $13.67. The firm’s fifty day moving average is $7.91 and its two-hundred day moving average is $5.80.

Kyverna Therapeutics (NASDAQ:KYTX) last issued its quarterly earnings data on Wednesday, November 12th. The company reported ($0.85) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.97) by $0.12. As a group, analysts forecast that Kyverna Therapeutics will post -3.29 EPS for the current fiscal year.

Insider Transactions at Kyverna Therapeutics

In related news, Director Beth C. Seidenberg bought 133,333 shares of the business’s stock in a transaction dated Thursday, December 18th. The shares were purchased at an average price of $7.50 per share, with a total value of $999,997.50. Following the transaction, the director owned 869,317 shares in the company, valued at $6,519,877.50. This trade represents a 18.12% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CTO Karen Marie Walker sold 23,998 shares of the stock in a transaction on Monday, December 15th. The shares were sold at an average price of $12.20, for a total value of $292,775.60. Following the sale, the chief technology officer owned 22,636 shares in the company, valued at $276,159.20. The trade was a 51.46% decrease in their position. The disclosure for this sale is available in the SEC filing.

Institutional Investors Weigh In On Kyverna Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Bank of America Corp DE lifted its holdings in shares of Kyverna Therapeutics by 41.6% in the 4th quarter. Bank of America Corp DE now owns 21,788 shares of the company’s stock worth $81,000 after acquiring an additional 6,400 shares during the last quarter. Cubist Systematic Strategies LLC raised its position in Kyverna Therapeutics by 31.1% in the 1st quarter. Cubist Systematic Strategies LLC now owns 68,628 shares of the company’s stock worth $132,000 after purchasing an additional 16,267 shares during the period. AQR Capital Management LLC purchased a new stake in Kyverna Therapeutics in the 1st quarter worth about $137,000. Rhumbline Advisers lifted its stake in Kyverna Therapeutics by 22.0% in the first quarter. Rhumbline Advisers now owns 31,614 shares of the company’s stock worth $61,000 after purchasing an additional 5,694 shares during the last quarter. Finally, Vanguard Personalized Indexing Management LLC boosted its position in shares of Kyverna Therapeutics by 25.2% during the second quarter. Vanguard Personalized Indexing Management LLC now owns 19,122 shares of the company’s stock valued at $59,000 after buying an additional 3,847 shares during the period. Hedge funds and other institutional investors own 18.08% of the company’s stock.

About Kyverna Therapeutics

Kyverna Therapeutics is a clinical‐stage biotechnology company dedicated to developing engineered regulatory T‐cell (Treg) therapies for the treatment of autoimmune and inflammatory diseases. Leveraging a proprietary platform for the isolation, expansion and modification of Treg cells, the company aims to restore immune homeostasis in patients by delivering antigen‐specific cell therapies that selectively target diseased tissues while minimizing systemic immunosuppression.

The company’s lead programs include an allogeneic Treg candidate in clinical development for ulcerative colitis, with additional preclinical assets focused on rheumatoid arthritis and other chronic inflammatory conditions.